| Erica Pearl Hoversland, PHARMD | |
|
760 Wicks Ln, Billings, MT 59105-4427 | |
| (406) 238-2475 | |
| (406) 238-5546 |
| Full Name | Erica Pearl Hoversland |
|---|---|
| Gender | Female |
| Speciality | Pharmacist - Ambulatory Care |
| Location | 760 Wicks Ln, Billings, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831665793 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P2201X | Pharmacist - Ambulatory Care | PHA-PHA-LIC-47860 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Erica Pearl Hoversland, PHARMD 760 Wicks Ln, Billings, MT 59105-4427 Ph: (406) 238-2475 | Erica Pearl Hoversland, PHARMD 760 Wicks Ln, Billings, MT 59105-4427 Ph: (406) 238-2475 |
News Archive
Eighty-three percent of the owners of small businesses surveyed across Michigan do not support a government-operated health care plan as a public option for insurance, according to a new survey of the members of the Michigan Business and Professional Association (MBPA) and the Michigan Food and Beverage Association (MFBA) headquartered in Warren. This is intriguing data as Michigan's economy has been under national scrutiny and the bills were designed to help small business.
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell - DLBCL (ABC-DLBCL), remains a major therapeutic challenge.
The decision came out of the blue. "Your husband isn't going to get any better, so we can't continue services," an occupational therapist told Deloise "Del" Holloway in early November. "Medicare isn't going to pay for it."
A protein called isocitrate dehydrogenase is present at high levels in lung cancers and can be detected in the blood, making it a noninvasive diagnostic marker for lung cancers, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Forest Laboratories, Inc. and Nycomed today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roflumilast. Roflumilast was reviewed as a potential treatment to reduce COPD exacerbations associated with chronic bronchitis in patients at risk for exacerbations.
› Verified 9 days ago
Hannah Elizabeth Johnson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1649 Main St, Billings, MT 59105 Phone: 406-254-2842 | |
David Sanks, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2525 King Ave W, Billings, MT 59102 Phone: 406-652-9688 | |
Joshua Teynor, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1602 Main St, Billings, MT 59105 Phone: 406-245-0178 | |
Gerald Robbin Fisher, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3333 Grand Ave, Billings, MT 59102 Phone: 406-652-1620 | |
Dr. Natalie Marie Waterfall, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 670 Main St, Billings, MT 59105 Phone: 406-245-6979 | |
Barbara Metzger, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2290 King Ave W, Billings, MT 59102 Phone: 406-656-8556 | |
Kailey Klinger, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1775 Spring Creek Lane, Billings, MT 59102 Phone: 406-373-3500 Fax: 406-373-3607 |